



## Mortality, critical illness, and mechanical ventilation among hospitalized patients with COVID-19 on therapeutic anticoagulants



Niti G. Patel<sup>a,\*</sup>, Ajay Bhasin<sup>a</sup>, Joseph M. Feinglass<sup>b</sup>, Michael P. Angarone<sup>c</sup>, Elaine R. Cohen<sup>a</sup>, Jeffrey H. Barsuk<sup>a</sup>

<sup>a</sup> Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, IL, USA

<sup>b</sup> Northwestern University Feinberg School of Medicine, Division of General Internal Medicine and Geriatrics, Chicago, IL, USA

<sup>c</sup> Northwestern University Feinberg School of Medicine, Division of Infectious Diseases, Department of Medicine, Chicago, IL, USA

### ARTICLE INFO

#### Keywords:

Anticoagulants  
COVID-19  
Coagulopathy  
Venous thromboembolism (VTE)

### ABSTRACT

**Background:** COVID-19 is associated with hypercoagulability and increased incidence of thrombosis. We compared the clinical outcomes of adults hospitalized with COVID-19 who were on therapeutic anticoagulants to those on prophylactic anticoagulation.

**Materials and methods:** We performed an observational study of adult inpatients' with COVID-19 from March 9 to June 26, 2020. We compared patients who were continued on their outpatient prescribed therapeutic anticoagulation and those who were newly started on therapeutic anticoagulation for COVID-19 (without other indication) to those who were on prophylactic doses. The primary outcome was overall death while secondary outcomes were critical illness (World Health Organization Ordinal Scale for Clinical Improvement score  $\geq 5$ ), mechanical ventilation, and death among patients who first had critical illness. We adjusted for age, sex, race, body mass index (BMI), Charlson score, glucose on admission, and use of antiplatelet agents.

**Results:** Of 1716 inpatients with COVID-19, 171 patients were continued on their therapeutic anticoagulation and 78 were started on new therapeutic anticoagulation for COVID-19. In patients continued on home therapeutic anticoagulation, there were no differences in overall death, critical illness, mechanical ventilation, or death among patients with critical illness compared to patients on prophylactic anticoagulation. In patients receiving new therapeutic anticoagulation for COVID-19, there was increased death (OR 5.93; 95% CI 3.71–9.47), critical illness (OR 14.51; 95% CI 7.43–28.31), need mechanical ventilation (OR 11.22; 95% CI 6.67–18.86), and death after first having critical illness (OR 5.51; 95% CI 2.80–10.87).

**Conclusions:** Therapeutic anticoagulation for inpatients with COVID-19 was not associated with improved outcomes.

### 1. Introduction

Adults hospitalized with COVID-19 are at increased risk of thromboembolic disease [1–8]. This has been attributed to COVID-19-associated blood hyperviscosity [9] and vascular endotheliitis [10–12], which suggests that therapeutic strategies directed solely at the coagulation cascade, may be inadequate. A study of an ICU using routine duplex ultrasonography of the lower extremity in critically-ill COVID-19 patients found a high incidence of venous thromboembolism despite therapeutic anticoagulation [13].

There are no randomized controlled trials and few observational cohort studies addressing the potential benefits and harms of

anticoagulating hospitalized patients with COVID-19. Paranjpe et al. reported [14] that therapeutic anticoagulation treatment reduced COVID-19-associated mortality among patients on mechanical ventilation, while Tang et al. reported [15] that anticoagulation treatment reduced COVID-19-associated mortality among patients with sepsis-induced coagulopathy. However, both of these prior observational studies failed to account for survivorship bias; and the analysis by Tang et al. lacked generalizability as three-quarters of screened patients were excluded from their analysis [16,17]. Despite the paucity of available evidence, a recent CHEST Guideline and Expert Panel Report recommended that hospitalized COVID-19 patients who are acutely-ill or critically-ill and without a contraindication to

\* Corresponding author. 251 E. Huron Street, Feinberg 16 -738, Chicago, 60611, IL, USA.

E-mail address: [Niti.Patel@nm.org](mailto:Niti.Patel@nm.org) (N.G. Patel).

<https://doi.org/10.1016/j.tru.2020.100027>

Received 17 October 2020; Received in revised form 6 December 2020; Accepted 8 December 2020

2666-5727/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

anticoagulants be prescribed thromboprophylaxis anticoagulant with low-molecular-weight heparin (LMWH) or fondaparinux [18].

In this study, we evaluated the outcomes of adults hospitalized with COVID-19 who either continued therapeutic anticoagulants previously prescribed or who were newly started on anticoagulants during hospitalization. We hypothesized that patients who were prescribed therapeutic anticoagulants would have better outcomes than those who were on prophylactic anticoagulation while hospitalized.

## 2. Methods

We performed an observational cohort study of hospitalized adults with COVID-19 from ten hospitals affiliated with Northwestern Medicine between March 9 and June 26, 2020. Northwestern Medicine is an integrated academic health system in the Chicagoland area. We evaluated clinical outcomes among patients who continued their home therapeutic anticoagulation regimen and those who were newly started on anticoagulants to those who were started on prophylactic anticoagulation during their COVID-19 hospitalization. Clinical outcomes were classified according to the World Health Organization (WHO) Ordinal Scale for Clinical Improvement (Table 1) [19]. The Northwestern University Institutional Review Board approved this study (Approval Reference STU00212532).

### 2.1. Procedure

Data was extracted from the Northwestern University Enterprise Data Warehouse (NUEDW), an integrated database derived from the clinical data of all patients at our health system's 10 hospitals, each of which use electronic medical records exclusively. The study cohort comprised adults (age  $\geq 18$  years old) hospitalized with COVID-19 (ICD-10 code) who were either discharged or died during the study period. We evaluated patients who had been prescribed therapeutic anticoagulation prior to hospitalization and who then continued therapeutic anticoagulation during hospitalization. We also evaluated patients who had not been prescribed therapeutic anticoagulation prior to hospitalization and who then began therapeutic or prophylactic anticoagulation during hospitalization. The anticoagulants specified in the database included those used at Northwestern Medicine: apixaban, argatroban, bivalirudin, dabigatran, dalteparin, edoxaban, enoxaparin, fondaparinux, heparin, rivaroxaban, and warfarin. One author (NGP) manually reviewed the records for the index hospitalization for each patient who received at least one dose of therapeutic anticoagulation to determine the indication for anticoagulation and whether therapeutic anticoagulation had been prescribed prior to admission or was newly started while hospitalized. We categorized patients into the following six groups: continued home therapeutic anticoagulation, started therapeutic anticoagulation for concern of COVID-19 induced vasculopathy (no known other indication) during hospitalization, started therapeutic anticoagulation for new venous thromboembolism (VTE) during hospitalization, started therapeutic anticoagulation for new atrial fibrillation during hospitalization,

**Table 1**  
World Health organization (WHO) Ordinal scale for clinical improvement.

Patient state	Descriptor	Score
Uninfected Ambulatory	No clinical or virological evidence of infection	0
	No limitation of activities	1
Hospitalized mild disease	Limitation of activities	2
	Hospitalized, no oxygen therapy	3
Hospitalized severe disease	Oxygen by mask or nasal prongs	4
	Non-invasive ventilation or high-flow oxygen	5
	Intubation and mechanical ventilation	6
Dead	Ventilation + additional organ support-vasopressors, Renal Replacement Therapy, Extracorporeal membrane oxygenation	7
	Death	8

prophylactic dose anticoagulation during hospitalization, or no anticoagulation during hospitalization. We also collected information on age, sex, race, body mass index (BMI), Charlson score, admission blood glucose readings, use of antiplatelet agent (aspirin, clopidogrel, prasugrel, or ticagrelor), ICD-10 codes associated with admission, and outcomes from the WHO Ordinal Scale (Table 2). Another author (JHB) performed manual chart review on missing admission glucose levels because the original NUEDW query did not return an admission plasma glucose for a small number of patients. Admission blood glucose was assessed because hyperglycemia is an independent predictor of mortality in patients with COVID-19, regardless of diabetes diagnosis [20–22]. For patients with multiple admissions, the hospitalization with the worst WHO outcome was analyzed.

We compared patients' prescribed therapeutic anticoagulants (either continued from home or started in the hospital) to prophylactic anticoagulants on four clinical outcomes: overall death (primary outcome), critical illness (as defined as scores  $\geq 5$  on the WHO COVID-19 eight-point ordinal scale), need for mechanical ventilation, and death in critical illness (patients who first had critical illness before dying; WHO score 5–7) (secondary outcomes).

### 2.2. Measurement

The percentage of overall deaths was calculated as the number of patients who died divided by the *total* number of discharges and deaths. The percentage of patients with critical illness, mechanical ventilation, and death among patients who first had critical illness was calculated as the number of patients with each outcome divided by the number of critically ill patients who were discharged or died.

### 2.3. Analysis

We calculated the Charlson comorbidity index for each admission [21,22]. We used the Chi-square test to determine the significance of differences in baseline demographic and clinical characteristics and clinical outcomes between the six anticoagulation therapy groups. A p-value of  $< 0.01$  was used as the threshold for statistical significance in these bivariate analyses to adjust for multiple comparisons. Poisson regression was used to estimate associations between patient attributes and exposures and the likelihood of death, as the incidence rate ratio is a closer approximation to relative risk given the observed 7.3% overall death rate in this cohort [23]. Multiple logistic regression was used to determine associations between the six anticoagulation therapy groups with the likelihood of critical illness, need for mechanical ventilation and death amongst those with critical illness. Prophylactic anticoagulation was used as the reference group in regression models as this is the standard of care in our hospital. Regression models were adjusted for age, sex, race and ethnicity, body mass index (BMI), Charlson score, glucose on admission, and use of antiplatelet agents. Age, BMI, Charlson score, and blood glucose were categorized for ease of interpretation of odds ratios [24,25]. Sensitivity analyses were performed for all four regression models controlling for pre-existing hypertension, diabetes, asthma, chronic obstructive pulmonary disease, kidney disease, congestive heart failure, stroke, peripheral vascular disease, coronary artery disease, malignancy, or immunodeficiency in place of the Charlson score. All statistical analyses were performed using SPSS® Version 26 (Armonk, NY) and Stata Version 15.1 (College Station, TX).

## 3. Results

We identified 1716 adults hospitalized with COVID-19 of whom 372 were on therapeutic anticoagulation during their admission. Manual chart review for each of these patients confirmed their COVID-19 diagnosis and assigned each patient to one of the six anticoagulation groups. Therapeutic anticoagulation had been prescribed prior to hospitalization and was subsequently continued during hospitalization for 171 patients

**Table 2**  
Demographics and clinical outcomes of patients hospitalized with COVID-19 based on prescribed anticoagulant.

Variable	Total Study Population (N = 1716) %	Home Tx AC Continued (N = 171) %	Tx AC started for COVID Coagulopathy (N = 78) %	Tx AC started for new VTE (N = 99) %	Tx AC started for new Atrial Fibrillation (N = 24) %	VTE Prophylaxis (N = 1298) %	No Tx AC or VTE Prophylaxis (N = 46) %
<b>Demographics</b>							
Age <sup>a</sup>							
18–44	22.1	5.3	16.7	18.2	8.3	25.0	26.1
45–59	29.6	11.1	28.2	33.3	0.0	33.0	13.0
60–69	21.6	22.8	25.6	25.3	33.3	20.8	17.4
70–79	14.1	26.9	17.9	18.2	54.2	10.9	21.7
>80	12.6	33.9	11.5	5.1	4.2	10.3	21.7
Male <sup>b</sup>	54.5	56.1	59.0	74.7	58.3	52.7	45.7
Race <sup>a</sup>							
White	35.6	63.2	32.1	23.2	45.8	32.4	52.2
Black	16.8	19.9	14.1	28.3	8.3	16.2	8.7
Hispanic	38.6	11.7	46.2	38.4	37.5	42.0	32.6
Other	8.9	5.3	7.7	10.1	8.3	9.5	6.5
BMI							
Missing weight	5.7	6.4	0.0	1.0	0.0	6.2	8.7
18.5–24.9	21.4	22.2	21.8	22.2	29.2	20.9	26.1
25.0–29.9	28.3	29.8	25.6	33.3	29.2	28.1	21.7
30.0–39.9	33.0	31.6	28.2	33.3	33.3	33.3	37.0
>40	11.7	9.9	24.4	10.1	8.3	11.5	6.5
Charlson score <sup>a</sup>							
0	13.9	1.2	7.7	8.1	4.2	16.3	21.7
1	16.4	3.5	5.1	19.2	0.0	19.2	8.7
2–3	26.1	7.6	32.1	29.3	29.2	28.5	8.7
4–5	16.4	21.1	21.8	18.2	20.8	15.2	17.4
6–7	11.2	21.1	14.1	18.2	29.2	8.7	17.4
>8	16.0	45.6	19.2	7.1	16.7	12.2	26.1
<b>Clinical characteristics</b>							
Glucose on admission <sup>b,c</sup>							
<81	2.3	4.1	3.8	0.0	4.2	2.2	0.0
81–126	51.0	53.8	32.1	40.4	29.2	52.5	63.0
127–180	27.7	28.7	37.2	33.3	54.2	26.2	26.1
181–350	15.8	12.9	21.8	20.2	8.3	15.9	6.5
>351	3.1	0.6	5.1	6.1	4.2	3.1	4.3
Antiplatelet agent	16.5	22.8	19.2	16.2	12.5	15.6	17.4
Hypertension <sup>a</sup>	58.6	84.2	61.5	65.7	83.3	53.9	63.0
Diabetes <sup>a</sup>	34.7	44.4	56.4	36.4	25.0	32.6	21.7
Asthma	10.7	12.3	11.5	6.1	16.7	11.0	2.2
Chronic obstructive pulmonary disease <sup>a</sup>	10.7	24.6	16.7	9.1	20.8	8.5	10.9
Kidney disease <sup>a</sup>	19.3	41.5	21.8	23.2	29.2	15.6	23.9
Congestive heart failure <sup>a</sup>	15.4	53.8	17.9	18.2	25.0	9.6	23.9
History of stroke <sup>a</sup>	5.9	19.9	5.1	5.1	12.5	4.1	6.5
Peripheral artery disease <sup>a</sup>	5.8	14.0	7.7	5.1	8.3	4.7	4.3
Coronary artery disease <sup>a</sup>	5.1	13.5	7.7	3.0	4.2	3.8	13.0
Malignancy (solid/heme)	10.10	19.30	11.50	10.10	8.30	8.50	21.70
Immunodeficiency	1.3	1.8	0.0	1.0	8.4	1.3	2.2
<b>Outcomes</b>							
Overall death <sup>a</sup>	7.3	12.3	37.2	13.1	16.7	4.1	10.9
Critical illness <sup>a</sup>	32.3	36.3	85.9	71.7	75.0	25.1	23.9
Mechanical ventilation <sup>a</sup>	14.8	12.9	60.3	51.5	37.5	9.4	6.5
Death in critical illness <sup>a,d</sup>	19.3	24.2	43.2	23.9	22.2	12.6	45.5

No AC = did not receive anticoagulation

Tx = Therapeutic

AC = Anticoagulation

VTE= Venous thromboembolism a. P < 0.001

b. P < 0.01

c. 2 non-diabetic patients did not have admission glucose levels (their closest glucose level to admission was used for analysis – 1 from 2 months before and 1 at 1 year before admission)

d. Group included only critically ill patients (Total: N = 555; Home AC: N = 62; Tx AC started without etiology: N = 67; Tx AC started for new VTE: N = 71; Tx AC started for new atrial fibrillation: N = 18; VTE prophylaxis: N = 326; No AC: N = 11)

(10.0%). Therapeutic anticoagulation was initiated de novo during hospitalization for 201 patients (11.7%). Prophylactic anticoagulation was given during hospitalization for 1298 (75.6%). 46 patients (2.7%) did not receive therapeutic or prophylactic anticoagulation. Of the 201 patients newly started on therapeutic anticoagulation while hospitalized, 99 (5.8%) were treated for new VTE, 24 (1.4%) for new atrial fibrillation,

and 78 (4.5%) for COVID-19 disease without other indications. Of the 78 patients who received therapeutic anticoagulation for COVID-19, total duration of anticoagulation was a median 4 days [Interquartile range (IQR) 2–7 days].

In bivariate analyses (Table 2), those patients continued on prior to admission anticoagulation were more likely to be older, have higher

Charlson scores, and have more frequent comorbid conditions compared to those beginning prophylactic anticoagulation while hospitalized. Patients newly started on therapeutic anticoagulation compared to those on prophylactic anticoagulation were more likely to have higher Charlson score and more frequent comorbid conditions. Table 2 also shows that patients on therapeutic anticoagulation therapy (both continued outpatient and new inpatient) had worse primary outcomes of overall death and secondary outcomes of critical illness, mechanical ventilation, and death in critically ill compared to those on prophylactic doses. One hundred twenty-five patients in our health system died due to COVID-19 disease (7.3%). Eighteen deaths occurred without critical illness status (WHO score 3–4) and 107 deaths occurred in those who first had critical illness (WHO score 5–7). The mortality rate was 19.3% in critically ill patients.

After adjusting for covariates, there was no difference in death, critical illness, mechanical ventilation, or death in critical illness among patients continued on therapeutic anticoagulation prescribed prior to admission when compared to patients who received prophylactic anticoagulation (Table 3). Of note, patients who were newly started on therapeutic anticoagulation in the hospital had worse clinical outcomes (Table 3). Of the patients who received empiric therapeutic anticoagulation for COVID-19 infection, there was an increased risk of overall death (OR 5.93; 95% CI 3.71–9.47), critical illness (OR 14.51; 95% CI 7.43–28.31), mechanical ventilation (OR 11.22; 95% CI 6.67–18.86), and death in critical illness (OR 5.51; 95% CI 2.80–10.87). Of note, from the subjects who received empiric therapeutic anticoagulation for COVID-19 infection, 85.9% had a critical illness status.

**Table 3**

Poisson and multiple logistic regression analyses of 1716 patients hospitalized with COVID-19 the incidence rate ratio [IRR; (95% CI)] or the odds ratios [OR; 95% confidence interval (CI)] of patient anticoagulation status with overall death, critical illness, mechanical ventilation, and death among critical patients.

Variable	Overall Death IRR (95% CI) N = 125	Critical illness (WHO score >5) OR (95% CI) N = 555	Mechanical Ventilation OR (95% CI) N = 254	Death in Critical OR (95% CI) N = 125
Home therapeutic Anticoagulation continued	1.10 (0.65–1.86)	1.18 (0.80–1.72)	1.07 (0.63–1.83)	0.89 (0.42–1.89)
Therapeutic Anticoagulation started for COVID-19 infection	5.93 (3.71–9.47)	14.51 (7.43–28.31)	11.22 (6.67–18.86)	5.51 (2.80–10.87)
Therapeutic Anticoagulation started for new venous thromboembolism	3.13 (1.66–5.93)	6.75 (4.19–10.87)	9.03 (5.66–14.41)	2.08 (0.94–4.61)
Therapeutic Anticoagulation started for new Atrial fibrillation	2.18 (0.76–6.22)	6.47 (2.44–17.17)	3.97 (1.61–9.81)	1.62 (0.44–5.98)
No prophylaxis or therapeutic anticoagulation	1.72 (0.73–4.03)	0.74 (0.37–1.52)	0.55 (0.16–1.87)	4.20 (0.95–18.60)
Home antiplatelet	1.09 (0.72–1.64)	0.93 (0.68–1.27)	1.08 (0.72–1.62)	1.37 (0.77–2.42)
<b>Age (reference age 45–59)</b>				
18–44	1.36 (0.57–3.28)	0.79 (0.54–1.14)	1.16 (0.71–1.92)	1.43 (0.49–4.17)
60–69	1.30 (0.69–2.46)	0.99 (0.69–1.41)	1.24 (0.79–1.94)	1.82 (0.83–3.97)
70–79	1.31 (0.65–2.65)	1.09 (0.70–1.69)	0.89 (0.51–1.54)	1.36 (0.55–3.37)
>80	2.36 (1.16–4.83)	0.90 (0.55–1.49)	0.42 (0.21–0.84)	2.74 (1.03–7.32)
Male	1.66 (1.12–2.47)	1.75 (1.37–2.22)	1.53 (1.10–2.12)	1.51 (0.88–2.61)
<b>Race (reference white)</b>				
Black	0.53 (0.30–0.95)	0.76 (0.53–1.08)	1.23 (0.79–1.92)	0.45 (0.21–0.95)
Hispanic	0.92 (0.56–1.50)	1.05 (0.78–1.41)	1.29 (0.86–1.92)	0.71 (0.37–1.37)
Other	0.20 (0.05–0.81)	0.85 (0.54–1.32)	1.18 (0.65–2.16)	0.20 (0.04–0.93)
<b>BMI (reference BMI &lt;24.9)</b>				
25.0–29.9	1.15 (0.71–1.87)	1.34 (0.98–1.84)	1.28 (0.83–2.00)	0.86 (0.44–1.68)
30.0–39.9	1.39 (0.86–2.24)	1.56 (1.15–2.13)	1.79 (1.17–2.74)	1.26 (0.65–2.46)
>40	1.51 (0.75–3.02)	2.31 (1.51–3.53)	2.55 (1.48–4.40)	1.24 (0.49–3.11)
<b>Charlson score (reference score 0)</b>				
1	1.84 (0.16–20.73)	1.02 (0.64–1.64)	0.78 (0.39–1.54)	2.30 (0.19–27.91)
2–3	9.86 (1.24–78.52)	1.50 (0.92–2.43)	1.37 (0.71–2.63)	7.80 (0.90–67.97)
4–5	13.12 (1.58–108.64)	1.39 (0.80–2.40)	1.88 (0.91–3.87)	9.48 (1.03–87.63)
6–7	19.60 (2.32–165.83)	3.45 (1.90–6.29)	3.85 (1.77–8.39)	11.74 (1.23–112.15)
>8	32.24 (3.86–269.26)	2.85 (1.56–5.20)	3.84 (1.74–8.45)	22.41 (2.37–211.94)
<b>Glucose level (reference 80–126 mg/dL)</b>				
<80	2.06 (0.90–4.71)	1.24 (0.58–2.64)	1.43 (0.55–3.74)	4.06 (1.06–15.62)
127–180	1.47 (0.95–2.27)	1.35 (1.03–1.77)	1.56 (1.08–2.25)	1.42 (0.78–2.59)
181–350	1.43 (0.86–2.39)	1.98 (1.43–2.75)	1.77 (1.16–2.71)	1.30 (0.65–2.61)
>351	2.19 (0.89–5.37)	1.26 (0.64–2.47)	2.11 (0.95–4.65)	2.25 (0.67–7.52)

Therapeutic anticoagulation started for new VTE was associated with increased risk of overall death (OR 3.13; 95% CI 1.66–5.93), critical illness (OR 6.75; 95% CI 4.19–10.87) and needing mechanical ventilation (OR 9.03; 95% CI 5.66–14.41). Therapeutic anticoagulation started for new atrial fibrillation had increased risk of critical illness (OR 6.47; 95% CI 2.44–17.17) and needing mechanical ventilation (OR 3.97; 95% CI 1.61–9.81). Increased age, male sex, BMI and increased Charlson score were associated with worse outcomes (Table 3). These results were unchanged in the sensitivity analysis.

**4. Discussion**

Patients hospitalized with COVID-19 who were prescribed therapeutic anticoagulation prior to hospitalization and who were continued on therapeutic anticoagulation while hospitalized had no difference in primary outcomes of overall death compared to patients who started prophylactic anticoagulation while hospitalized; there was also no difference between these groups for secondary outcomes of critical illness, mechanical ventilation, or death in critical illness. Patients who were started on anticoagulation for COVID-19 without evidence of thrombosis, new VTE, or new atrial fibrillation had worse outcomes compared to patients who were on prophylactic anticoagulation, even after controlling for age, sex, race, BMI, Charlson score, glucose on admission, and use of antiplatelet agents.

Our study findings add to a growing body of observational studies evaluating the effects of therapeutic anticoagulation in patients with



COVID-19. In the study by Parajpe et al. patients on mechanical ventilation were less likely to die if they were on therapeutic anticoagulation (29.1% vs. 62.7%) [14]. In two other observational study by Tang et al. and Ayerbe et al. patients with COVID-19 had a mortality benefit if they received low molecular weight heparin (LMWH) or heparin, respectively [15,26]. However, neither of these two studies specified whether the dose of anticoagulant was therapeutic or prophylactic. Two other studies limited by low numbers reported lower mortality in patients receiving therapeutic anticoagulants [27,28]. In contrast, a study of nursing home patients suggested that continuation of oral therapeutic anticoagulation in patients with COVID-19 infection did not have a mortality benefit [29]. Additionally, another observation study posted on [medrxiv.org](https://medrxiv.org) (that has not yet undergone peer review) reported a higher mortality rate among patients with COVID-19 who received empiric therapeutic anticoagulation with other indications [30]. Based on current evidence, we do not believe firm recommendations for or against empiric anticoagulation in patients with COVID-19 can be made. In our hospitals, we do not routinely use therapeutic anticoagulation for patients with COVID-19 infection without other indications [31,32].

Our study had other significant findings. First, of the patients who were not already on therapeutic anticoagulation, 6.4% of patients with COVID-19 were anticoagulated for a newly diagnosed VTE similar to other studies on the incidence of VTE in COVID-19 [4,33]. Second, our study confirms previously identified risk factors for worse outcomes in COVID-19 including sex, BMI, blood glucose levels, and comorbid conditions [20,34,35]. However, the overall mortality rate (7.3%) of patients in our study was lower than that reported in other studies. Recent studies out of the New York City area and Louisiana showed inpatient mortality rates between 21 and 24% [35,36]. Our mortality rate may be lower because our health system never became overwhelmed, patients were cared for by a multi-disciplinary team that rounded twice daily, and clinicians in our ICUs treated ventilated patients with low volume, high peep strategies as well as prone positioning [37,38].

In our cohort, dexamethasone was not widely used during the study period. It seems plausible that routine prophylaxis against or treatment of endotheliitis with glucocorticosteroids may result in reduced incidence of thrombosis with reductions in overall mortality, as was reported in the RECOVERY study [39,40]. However, the optimal timing of administration of dexamethasone during COVID-19 illness is not clear as glucocorticosteroids may also suppress innate and adaptive immune response, which may result in higher viral load and greater excursion of blood glucose values, leading to worse outcomes in some patients [41,42].

Our study has several limitations. First, our-cohort definition and clinical data relied on the accuracy of ICD-10 coding for disease diagnoses, although we did manually review 372 (22%) charts which confirmed COVID-19 infection and assessed timing and indication for therapeutic anticoagulation. Second, our study was observational, and despite attempting to control for confounding clinical variables, there may have been confounding by indication. We were unable to determine why therapeutic anticoagulation was started for COVID-19 coagulopathy—whether this was physician preference and/or a marker of more severe illness is unknown. Although patients on therapeutic anticoagulation may have had unmeasured risk factors, we did not find any benefit of therapeutic anticoagulation in patients with COVID-19. However, in our cohort of patients who were already critically ill, patients started on anticoagulation had 5.5 times the risk of dying. Third, we did not evaluate outcomes by individual anticoagulant drug. It is possible that the clinical effects of DOACs and LMWH differ in patients with COVID-19 [27,43]. Fourth, we did not control for the number of days patients received new therapeutic anticoagulation because we were unable to determine the timing of starting these medications within the course of COVID-19 infection. Finally, we did not assess the rate of bleeding in our population as it would require a detailed chart review of timing and severity of bleeding. Anticoagulation is a well-known risk factor for bleeding and risk of bleeding may be higher in patients with COVID-19 [33,44,45].

In conclusion, continuation of home therapeutic anticoagulation was associated with neither benefit nor harm in subjects hospitalized with COVID-19. Subjects with COVID-19 who had not previously been anticoagulated and who were empirically prescribed therapeutic anticoagulation during their hospitalization had worse outcomes. Our findings do not support routine use of therapeutic anticoagulation for patients with COVID-19 infection in the absence of other indications (i.e., atrial fibrillation or venous thromboembolism). Randomized controlled trials are currently underway to assess therapeutic anticoagulation in patients with COVID-19 [46].

## Funding/support

None.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgements

We would like to acknowledge Dr. Douglas Vaughan for his support of this project and Dr. Brady Stein for editorial feedback on the manuscript. We thank the countless clinicians, environmental and food services personnel, and other staff at Northwestern Medicine for their dedication to patient care during the COVID-19 pandemic.

## References

- [1] F.A. Klok, M.J.H.A. Kruip, N.J.M. van der Meer, et al., Incidence of thrombotic complications in critically ill ICU patients with COVID-19, *Thromb. Res.* 191 (2020) 145–147, <https://doi.org/10.1016/j.thromres.2020.04.013>.
- [2] A. Gupta, M.V. Madhavan, K. Sehgal, et al., Extrapulmonary manifestations of COVID-19, *Nat. Med.* 26 (7) (2020) 1017–1032, <https://doi.org/10.1038/s41591-020-0968-3>.
- [3] S. Bilaloglu, Y. Aphinyanaphongs, S. Jones, E. Iturrate, J. Hochman, J.S. Berger, Thrombosis in hospitalized patients with COVID-19 in a New York city health system, *J. Am. Med. Assoc.* (2020), <https://doi.org/10.1001/jama.2020.13372>. Published online July 20.
- [4] H. Al-Samkari, R.S. Karp Leaf, W.H. Dzik, et al., COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection, *Blood* 136 (4) (2020) 489–500, <https://doi.org/10.1182/blood.202006520>.
- [5] F. Potus, V. Mai, M. Lebre, et al., Novel insights on the pulmonary vascular consequences of COVID-19, *Am. J. Physiol. Lung Cell Mol. Physiol.* 319 (2) (2020) L277–L288, <https://doi.org/10.1152/ajplung.00195.2020>.
- [6] M.E. Colling, Y. Kanthi, COVID-19-associated coagulopathy: an exploration of mechanisms, *Vasc Med Lond Engl*. Published online June 19 (2020), <https://doi.org/10.1177/1358863X20932640>, 1358863X20932640.
- [7] F. Al-Ani, S. Chehade, A. Lazo-Langner, Thrombosis risk associated with COVID-19 infection. A scoping review, *Thromb. Res.* 192 (2020) 152–160, <https://doi.org/10.1016/j.thromres.2020.05.039>.
- [8] A. Trimaille, A. Curtiaud, B. Marchandot, et al., Venous thromboembolism in non-critically ill patients with COVID-19 infection, *Thromb. Res.* 193 (2020) 166–169, <https://doi.org/10.1016/j.thromres.2020.07.033>.
- [9] C.L. Maier, A.D. Truong, S.C. Auld, D.M. Polly, C.-L. Tanksley, A. Duncan, COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? *Lancet Lond Engl* 395 (10239) (2020) 1758–1759, [https://doi.org/10.1016/S0140-6736\(20\)31209-5](https://doi.org/10.1016/S0140-6736(20)31209-5).
- [10] R. Ferrandis, J.V. Llau, M. Quintana, et al., COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients? *Crit. Care* 24 (1) (2020) 332, <https://doi.org/10.1186/s13054-020-03052-9>.
- [11] C. Sardu, J. Gambardella, M.B. Morelli, X. Wang, R. Marfella, G. Santulli, Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence, *J. Clin. Med.* 9 (5) (2020), <https://doi.org/10.3390/jcm9051417>.
- [12] Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. *N. Engl. J. Med.*. Published online May 21, 2020. doi:10.1056/NEJMoa2015432.
- [13] J.-F. Llitjos, M. Leclerc, C. Chochois, et al., High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients, *J Thromb Haemost JTH* (2020), <https://doi.org/10.1111/jth.14869>. Published online April 22.
- [14] I. Paranjpe, V. Fuster, A. Lala, et al., Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19, *J. Am. Coll. Cardiol.* 76 (1) (2020) 122–124, <https://doi.org/10.1016/j.jacc.2020.05.001>.

- [15] N. Tang, H. Bai, X. Chen, J. Gong, D. Li, Z. Sun, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, *J. Thromb. Haemostasis* 18 (5) (2020) 1094–1099, <https://doi.org/10.1111/jth.14817>.
- [16] J.H. Maley, C.R. Petri, L.N. Brenner, et al., Anticoagulation, immortality, and observations of COVID-19, *Res Pract Thromb Haemost* 4 (5) (2020) 674–676, <https://doi.org/10.1002/rth2.12398>.
- [17] M. Dalager-Pedersen, J. Bodilsen, Thromboprophylaxis for medical inpatients with coronavirus disease 2019, *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. Published online May 23 (2020), <https://doi.org/10.1016/j.cmi.2020.05.021>.
- [18] L.K. Moores, T. Tritschler, S. Brosnahan, et al., Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and Expert Panel Report, *Chest*. Published online June 2 (2020), <https://doi.org/10.1016/j.chest.2020.05.559>.
- [19] Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization (<http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/> (opens in new tab)).
- [20] S. Wang, P. Ma, S. Zhang, et al., Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes, a multi-centre retrospective study. *Diabetologia* (2020), <https://doi.org/10.1007/s00125-020-05209-1>. Published online July 10.
- [21] K. Stavem, H. Hoel, S.A. Skjaker, R. Haagensen, Charlson comorbidity index derived from chart review or administrative data: agreement and prediction of mortality in intensive care patients, *Clin. Epidemiol.* 9 (2017) 311–320, <https://doi.org/10.2147/CLEP.S133624>.
- [22] V. Sundararajan, T. Henderson, C. Perry, A. Muggivan, H. Quan, W.A. Ghali, New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality, *J. Clin. Epidemiol.* 57 (12) (2004) 1288–1294, <https://doi.org/10.1016/j.jclinepi.2004.03.012>.
- [23] G. Zou, A modified Poisson regression approach to prospective studies with binary data, *Am. J. Epidemiol.* 159 (7) (2004) 702–706, <https://doi.org/10.1093/aje/kwh090>.
- [24] K.M. Flegal, B.K. Kit, H. Orpana, B.I. Graubard, Association of all-cause mortality with overweight and obesity using standard body mass index categories, *J. Am. Med. Assoc.* 309 (1) (2013) 71–82, <https://doi.org/10.1001/jama.2012.113905>.
- [25] A.D. Association, Diagnosis and classification of diabetes mellitus, *Diabetes Care* 27 (suppl 1) (2004) s5–s10, <https://doi.org/10.2337/diacare.27.2007.S5>.
- [26] L. Ayerbe, C. Risco, S. Ayis, The association between treatment with heparin and survival in patients with Covid-19, *J. Thromb. Thrombolysis* 50 (2) (2020) 298–301, <https://doi.org/10.1007/s11239-020-02162-z>.
- [27] R. Rossi, F. Coppi, M. Talarico, G. Boriani, Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era, *Eur. J. Intern. Med.* 77 (2020) 158–160, <https://doi.org/10.1016/j.ejim.2020.06.006>.
- [28] E. Secco, M. Pasqualetto, T. Bombardini, E. Picano, F. Rigo, A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy. *Kardiol Pol.* (2020), <https://doi.org/10.33963/KP.15489>. Published online July 6.
- [29] S.H. Brungs, R. Brüggemann, A.E.M.J.H. Linkens, et al., Mortality and the use of antithrombotic therapies among nursing home residents with COVID-19, *J. Am. Geriatr. Soc.* 68 (8) (2020) 1647–1652, <https://doi.org/10.1111/jgs.16664>.
- [30] J.K. Motta, R.O. Ogunnaik, R. Shah, et al., Clinical outcomes with the use of prophylactic versus therapeutic anticoagulation in COVID-19, *medRxiv* (2020), <https://doi.org/10.1101/2020.07.20.20147769>. Published online July 26, 2020.
- [31] B. Bikdeli, M.V. Madhavan, D. Jimenez, et al., COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review, *J. Am. Coll. Cardiol.* 75 (23) (2020) 2950–2973, <https://doi.org/10.1016/j.jacc.2020.04.031>.
- [32] L.B. Kreuziger, A. Lee, D. Garcia, A. Cuker, M. Cushman, M. DeSancho, J.M. Connors, COVID-19 and VTE-Anticoagulation - [hematology.org](https://www.hematology.org). Accessed June 9, <https://www.hematology.org:443/covid-19/covid-19-and-vte-anticoagulation>, 2020.
- [33] R. Patel, T. Bogue, P. Bindal, et al., Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19, *J Thromb Haemost JTH* (2020), <https://doi.org/10.1111/jth.15018>. Published online July 21.
- [34] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a Report of 72 314 cases from the Chinese center for disease control and prevention. *JAMA*. Published online February 24, 2020. doi:10.1001/jama.2020.2648.
- [35] S. Richardson, J.S. Hirsch, M. Narasimhan, et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area, *J. Am. Med. Assoc.* 323 (20) (2020) 2052–2059, <https://doi.org/10.1001/jama.2020.6775>.
- [36] E.G. Price-Haywood, J. Burton, D. Fort, L. Seoane, Hospitalization and mortality among black patients and white patients with covid-19, *N. Engl. J. Med.* (2020), <https://doi.org/10.1056/NEJMs2011686>.
- [37] A.E. Thompson, B.L. Ranard, Y. Wei, S. Jelic, Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure, *JAMA Intern Med.* Published online June 17 (2020), <https://doi.org/10.1001/jamainternmed.2020.3030>.
- [38] W. Alhazzani, M.H. Møller, Y.M. Arabi, et al., Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19), *Crit. Care Med.* 48 (6) (2020) e440–e469, <https://doi.org/10.1097/CCM.0000000000004363>.
- [39] W.J. Wiersinga, A. Rhodes, A.C. Cheng, S.J. Peacock, H.C. Prescott, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, *JAMA*. Published online July 10 (2020), <https://doi.org/10.1001/jama.2020.12839>.
- [40] RECOVERY Collaborative Group, P. Horby, W.S. Lim, et al., Dexamethasone in hospitalized patients with covid-19 - preliminary Report, *N. Engl. J. Med.* (2020), <https://doi.org/10.1056/NEJMoa2021436>. Published online July 17.
- [41] R.M. Johnson, J.M. Vinetz, Dexamethasone in the management of covid -19, *BMJ* 370 (2020) m2648, <https://doi.org/10.1136/bmj.m2648>.
- [42] C. Solinas, L. Perra, M. Aiello, E. Migliori, N. Petrosillo, A critical evaluation of glucocorticoids in the management of severe COVID-19, *Cytokine Growth Factor Rev.* (2020), <https://doi.org/10.1016/j.cytogfr.2020.06.012>. Published online June 24.
- [43] C.S. Kow, S.S. Hasan, Use of low-molecular-weight heparin in COVID-19 patients, *J Vasc Surg Venous Lymphat Disord* 8 (5) (2020) 900–901, <https://doi.org/10.1016/j.jvs.2020.06.006>.
- [44] S. Piran, S. Schulman, Treatment of bleeding complications in patients on anticoagulant therapy, *Blood* 133 (5) (2019) 425–435, <https://doi.org/10.1182/blood-2018-06-820746>.
- [45] R. Patel, T. Bogue, A. Koshy, P. Bindal, M. Merrill, W.C. Aird, K.A. Bauer, J.I. Zwicker, Postdischarge thrombosis and hemorrhage in patients with COVID-19, *Blood* 136 (11) (2020) 1342–1346, <https://doi.org/10.1182/blood.2020007938>.
- [46] Home - [ClinicalTrials.gov](https://clinicaltrials.gov), Accessed October 14, <https://clinicaltrials.gov/>, 2020.